Nomura Asset Management Co. Ltd. Sells 14,155 Shares of Moderna, Inc. (NASDAQ:MRNA)

Nomura Asset Management Co. Ltd. reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 12.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 100,180 shares of the company's stock after selling 14,155 shares during the period. Nomura Asset Management Co. Ltd.'s holdings in Moderna were worth $4,165,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP boosted its stake in shares of Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. boosted its position in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after buying an additional 297 shares during the period. Commonwealth Equity Services LLC grew its holdings in Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after acquiring an additional 345 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Moderna by 39.1% during the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after purchasing an additional 356 shares during the period. Finally, New Insight Wealth Advisors grew its stake in shares of Moderna by 4.4% in the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after purchasing an additional 358 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Barclays lowered Moderna from an "overweight" rating to an "equal weight" rating and cut their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Royal Bank of Canada reissued a "sector perform" rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. UBS Group lowered their price objective on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Finally, Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Moderna presently has a consensus rating of "Hold" and an average price target of $59.00.

Moderna Stock Performance

NASDAQ:MRNA traded down $0.62 during trading hours on Friday, reaching $25.11. The stock had a trading volume of 16,041,074 shares, compared to its average volume of 7,025,575. Moderna, Inc. has a 12-month low of $23.76 and a 12-month high of $170.47. The stock has a market cap of $9.71 billion, a P/E ratio of -2.71 and a beta of 2.23. The stock has a 50 day simple moving average of $33.55 and a 200 day simple moving average of $43.01.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.